Cyber Sale, Massive Discounts Await
I understand that I will be charged every 3 months for my cycle subscription.
Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
Research summary on Cardarine (also known as GW-501506).
It’s technically not a SARM — but it’s often grouped with them because of how it's used.
Cardarine is a PPAR delta agonist — which means it activates pathways in the tissue that turn stored fat into usable energy.
In research settings, Cardarine has been shown to:
✔ Increase respiratory oxygenation in lung tissue.
✔ Enhance fatty acid transport and oxidation.
✔ And support metabolic function — especially in skeletal muscle and cardiac tissue.
🔥 CARDIAC ENDURANCE:
In studies, Cardarine has shown to increase oxygen utilization in lung tissue — helping muscle tissue operate under higher workloads without depleting glycogen stores as rapidly.
🫓 FAT OXIDATION:
Cardarine activates genes involved in the fatty acid transport process. Additionally, it enhances intracellular fatty acid transport and oxidation, leading to more efficient energy utilization in muscle tissue.
⚡️ MUSCULAR ENDURANCE:
Cardarine enhances how efficiently cells produce energy — especially in skeletal muscle and heart tissue — allowing those systems to operate longer without fatiguing as quickly.
1. PPAR Promotes Running Endurance by Preserving Glucose <
https://www.cell.com/cell-metabolism/pdf/S1550-4131%2817%2930211-5.pdf
2. A metabolomic study of the PPAR agonist GW501516 for enhancing running endurance in Kunming mice
https://www.nature.com/articles/srep09884
3. Cardarine (GW501516) Effects on Improving Metabolic Syndrome
4. GW501516 (Cardarine): Pharmacological and Clinical Effects
https://www.scivisionpub.com/pdfs/gw501516-cardarine-pharmacological-and-clinical-effects-2879.pdf
5. Activation of PPAR signaling improves skeletal muscle oxidative metabolism
https://pmc.ncbi.nlm.nih.gov/articles/PMC4551122/
6. PPAR-agonist GW501516 ameliorates insulin resistance in mice
https://pubmed.ncbi.nlm.nih.gov/18684227/
7. Lipid effects of GW501516 in dyslipidemic subjects
Research summary on SR-9009 (also known as Stenabolic).
SR-9009 (Stenabolic) is technically not a SARM
SR-9009 (Stenabolic) is technically not a SARM — it is a Rev-ErbA agonist, influencing circadian rhythm and metabolism.
In research settings, it has been shown to:
✔ Increase metabolic rate.
✔ Enhance endurance performance.
✔ Support fat loss.
⚡ METABOLIC ACTIVATION:
Boosts basal metabolic rate and energy expenditure in preclinical studies.
🔥 ENDURANCE GAINS:
Improves running capacity in animal models.
🥩 FAT LOSS SUPPORT:
Enhances fat oxidation during exercise and rest.
1. Amador, Ariadna, Huitron-Resendiz, Salvador, Roberts, Amanda J, Kamenecka, Theodore M, Solt, Laura A, & Burris, Thomas P (2016). Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.. PloS one.
https://doi.org/10.1371/journal.pone.0162452
2. Amador, Ariadna, Kamenecka, Theodore M, Solt, Laura A, & Burris, Thomas P (2018). REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.. Biochemical pharmacology.
https://doi.org/10.1016/j.bcp.2018.01.009
3. Amador, Ariadna, Wang, Yongjun, Banerjee, Subhashis, Kameneka, Theodore M, Solt, Laura A, & Burris, Thomas P (2016). Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.. PloS one.
https://doi.org/10.1371/journal.pone.0151014
4. Amir, Mohammed, Campbell, Sean, Kamenecka, Theodore M, & Solt, Laura A (2020). Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell development.. Biochemical and biophysical research communications.
https://doi.org/10.1016/j.bbrc.2020.05.012
5. Borrmann, Helene, Davies, Rhianna, Dickinson, Matthew, Pedroza-Pacheco, Isabela, Schilling, Mirjam, Vaughan-Jackson, Alun, ... Zhuang, Xiaodong (2020). Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.. Scientific reports.
Research summary on MK-677
MK-677 (Ibutamoren) is technically not a SARM
MK-677 (Ibutamoren) is technically not a SARM — it is a growth hormone secretagogue, stimulating GH and IGF-1 release.
In research settings, it has been shown to:
✔ Increase growth hormone and IGF-1 levels.
✔ Promote muscle gain and fat loss.
✔ Improve sleep quality and recovery.
⚡ HORMONE BOOST:
MK-677 increases circulating growth hormone and IGF-1, supporting anabolic processes.
📊 BODY COMPOSITION:
May promote lean mass gains while reducing body fat percentage.
🔄 SLEEP & RECOVERY:
Improves REM sleep and overall recovery quality.
1. Abdul Ghafoor, Naeem, Rasuli, Sabina, Tanriverdi, Özgür, & Yildiz, Ayşegül (2025). Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.. Basic & clinical pharmacology & toxicology.
https://doi.org/10.1111/bcpt.14111
2. Arnott, Gareth, Brice, Heloise, Clayden, Jonathan, & Blaney, Emma (2008). Electrophile-induced dearomatizing spirocyclization of N-arylisonicotinamides: a route to spirocyclic piperidines.. Organic letters.
https://doi.org/10.1021/ol801092s
3. Bedendi, I, Gallo, M P, Malan, D, Levi, R C, & Alloatti, G (2001). Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle.. Life sciences.
https://doi.org/10.1016/s0024-3205(01)01312-1
4. Bennett, Kirstie A, Langmead, Christopher J, Wise, Alan, & Milligan, Graeme (2009). Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor.. Molecular pharmacology.
Explore the best stack options.
